文献速递类风湿关节炎

艾玛昔替尼(选择性JAK1抑制剂)治疗对传统合成改善病情抗风湿药应答不佳的中重度活动性类风湿关节炎:III期随机临床试验结果

Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial.
PubMed 文献 · Ann Rheum Dis · 2025-01-03

这项III期随机临床试验评估了选择性JAK1抑制剂艾玛昔替尼在中重度活动性类风湿关节炎且对传统合成改善病情抗风湿药应答不佳患者中的疗效与安全性。患者按1:1:1随机接受安慰剂(n=188)、艾玛昔替尼4 mg(n=189)或8 mg(n=189)每日一次,背景csDMARDs允许使用。第24周时,艾玛昔替尼4 mg组(70.4%)和8 mg组(75.1%)的ACR20应答率显著高于安慰剂组(40.4%;均p<0.0001)。

要点

  • 第24周ACR20应答率:艾玛昔替尼4 mg组70.4%、8 mg组75.1%,均显著高于安慰剂组40.4%(均p<0.0001)。
  • 两种剂量艾玛昔替尼的DAS28-CRP<2.6/≤3.2应答率在数值上高于安慰剂。
  • 安慰剂对照期间,4 mg组和8 mg组TEAE发生率分别为81.5%和90.5%,安慰剂组为79.3%;感染相关TEAE在艾玛昔替尼组略高。

核心结论

  • 艾玛昔替尼可能为对csDMARDs应答不佳的类风湿关节炎患者提供一种潜在治疗选择,其安全性特征在1年治疗期间总体可控,且与其他JAK抑制剂相似。

研究设计与样本

  • III期随机临床试验,患者按1:1:1随机接受安慰剂(n=188)、艾玛昔替尼4 mg(n=189)或艾玛昔替尼8 mg(n=189)每日一次,允许背景csDMARDs。
  • 24周后,安慰剂组患者转换为艾玛昔替尼4 mg继续治疗28周,艾玛昔替尼组患者维持原剂量继续治疗。
  • 主要终点为第24周达到美国风湿病学会20%改善标准(ACR20)的患者比例。
  • 试验注册号:NCT04333771。

主要发现

  • 第24周ACR20应答率:艾玛昔替尼4 mg组70.4%、8 mg组75.1%,均显著高于安慰剂组40.4%(均p<0.0001)。
  • 两种剂量艾玛昔替尼的DAS28-CRP<2.6/≤3.2应答率在数值上高于安慰剂。
  • 疗效和患者报告结局的改善持续至52周,且在24周后从安慰剂转换的患者中亦观察到改善。
  • 安慰剂对照期间,TEAE发生率在艾玛昔替尼4 mg组为81.5%、8 mg组为90.5%,安慰剂组为79.3%。
  • 感染相关TEAE在艾玛昔替尼组略高。

关键数值与推荐

  • ACR20应答率:艾玛昔替尼4 mg组70.4% vs 安慰剂组40.4%(p<0.0001);艾玛昔替尼8 mg组75.1% vs 安慰剂组40.4%(p<0.0001)。
  • DAS28-CRP<2.6/≤3.2应答率:两种剂量艾玛昔替尼在数值上高于安慰剂。
  • TEAE发生率:艾玛昔替尼4 mg组81.5%、8 mg组90.5%、安慰剂组79.3%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the efficacy/safety of ivarmacitinib, a selective Janus kinase (JAK) 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis (RA) who had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). METHODS: Patients were randomised (1:1:1) to receive either placebo (n=188), ivarmacitinib 4 mg (n=189) or ivarmacitinib 8 mg (n=189) once daily, with background csDMARDs allowed. After 24 weeks, patients on placebo switched to ivarmacitinib 4 mg for an additional 28 weeks, while those on ivarmacitinib continued their initial dosage. The primary endpoint was the proportion of patients achieving a 20% improvement in the American College of Rheumatology response criteria (ACR20) at week 24. RESULTS: At week 24, ACR20 response rates were significantly higher in the ivarmacitinib 4 mg (70.4%) and 8 mg (75.1%) groups compared with the placebo group (40.4%; both p<0.0001). Both ivarmacitinib doses achieved numerically higher Disease Activity Score 28-joint count C reactive protein of <2.6/≤3.2 response rates compared with placebo. Improvements in efficacy and patient-reported outcomes were sustained through 52 weeks and were noted in patients who switched from placebo after week 24. During the placebo-controlled period, treatment-emergent adverse events (TEAEs) occurred in 81.5% and 90.5% of patients in the ivarmacitinib 4 mg and 8 mg groups, versus 79.3% in the placebo group. Infection-related TEAEs were slightly higher in the ivarmacitinib groups. CONCLUSIONS: Ivarmacitinib may offer a potential therapeutic option for patients with RA who have an inadequate response to csDMARDs, with a safety profile that was generally manageable over 1 year of treatment and similar to other JAK inhibitors. TRIAL REGISTRATION NUMBER: NCT04333771.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Liu J, Jiang Y, Zhang S, et al. Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial. Ann Rheum Dis. 2025. PMID: 39919893. doi:10.1136/ard-2024-226385

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。